Drug Profile
Research programme: tyrosine kinase inhibitors - Ascepion Pharmaceuticals
Alternative Names: ASP-08001; ASP-08112; ASP-502DLatest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Ascepion Pharmaceuticals
- Class Small molecules
- Mechanism of Action Angiogenesis inhibitors; Protein tyrosine kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Solid-tumours in China (PO)
- 19 Jun 2012 Preclinical development is ongoing in China
- 21 Apr 2010 Preclinical trials in Solid tumours in China (PO)